



Tony Fitzgerald Appointed as a Director, Resignation of James Barrie as a Director

Melbourne, Australia, 6 February 2025 – InhaleRx Ltd (ASX: IRX), (**‘IRX’ or ‘the Company’**) an Australian healthcare company developing unique inhaled drug-device products to address unmet medical needs in the pain management and mental health sectors, is pleased to confirm the appointment of Tony Fitzgerald as a director of the Company, effective immediately.

As foreshadowed in previous announcements, the Company has been conducting a search for additional directors to join the IRX board with a view to complementing the board’s existing skills and experience.

Mr Fitzgerald is a Life Sciences entrepreneur, technologist and company director with extensive multi-country experience in private and public companies. He holds a Bachelor of Arts, Bachelor of Jurisprudence and Bachelor of Laws from the University of WA and a Master of Public Administration (Public Finance) from California State University, Fullerton.

Currently the CEO of molecular diagnostics company Avicena Systems Limited, Mr Fitzgerald adds significant skills and experience to the Board, including:

- Founder of ASX listed medical AI imaging company Resonance Health and cancer immunology company Selvax Pty Ltd, both medical technology spin outs from major Australian universities;
- Co-Founder of the Alerte group of AI technology companies including Alerte Digital Health and Singulariti Systems, and Avicena Systems Limited, the molecular diagnostics company that was named best Australian tech startup of the year in the 2021 national iAwards;
- Successfully concluded the echocardiogram data licensing transaction for Alerte , that enabled the later spin out of the Echo IQ technology to ASX listed Echo IQ Limited;
- Appraised and negotiated a variety of acquisitions, mergers and divestments and strategic partnering transactions in the life sciences, technology and resource related sectors (domestic and cross-border);
- Undertook public listings and capital raisings for companies in the life sciences, pharmaceutical distribution, artificial intelligence, agri-business, heavy engineering and resource sectors;
- Represented two major resource infrastructure projects in high level government negotiations (Australia, Korea and China); and
- Has served as director of various public companies over a twenty-five-year period.

The Board is delighted to appoint someone of Mr Fitzgerald’s calibre as a director and look forward to his contributions to the Company.

With Mr Fitzgerald’s appointment, James Barrie has resigned as a director of the Company also effective immediately, having filled the role on an interim basis since 1 March 2024. The Board thanks Mr Barrie for his contribution, who will continue to support the Board as Company Secretary.

An Appendix 3X for Mr Fitzgerald and Appendix 3Z for Mr Barrie are attached to this announcement.

Authorised by the Board of Directors.

For further information:

www.inhalerx.com.au

James Barrie, Company Secretary

Phone +61 3 8678 4091

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for IRX and the Company's shareholders. The first medical indications under investigation are Breakthrough Cancer Pain ('**BTcP**') and Panic Disorder ('**PD**'), both of which currently have limited safe and effective treatment options.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: INHALERX LIMITED
ACN: 611 845 820

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	MR TONY FITZGERALD
Date of appointment	6 FEBRUARY 2025

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Number & class of Securities

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: INHALERX LIMITED
ACN: 611 845 820

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	JAMES BARRIE
Date of last notice	16 DECEMBER 2024
Date that director ceased to be director	6 FEBRUARY 2025

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

Appendix 3Z

Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest <small>Note: Provide details of the circumstances giving rise to the relevant interest</small>	Number & class of securities
FESTING MILL PTY LTD <PETER PAN A/C> <i>Mr Barrie is a Director of Festing Mill Pty Ltd and a beneficiary of the Peter Pan A/C</i>	492,792 FULLY PAID ORDINARY SHARES

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.